The Power of Biomedical Research

The Washington Times (Washington, DC), July 9, 2003 | Go to article overview

The Power of Biomedical Research


Byline: Anthony S. Fauci, SPECIAL TO THE WASHINGTON TIMES

The anthrax attacks in the fall of 2001, which occurred soon after the catastrophic terrorist assaults on the World Trade Center and the Pentagon on September 11, have starkly exposed the vulnerability of the United States and, indeed, the rest of the world to bioterrorism.

In response, the U.S. government has committed an extraordinary sum (nearly $6.0 billion in fiscal year 2003) to develop strategies and countermeasures to protect Americans from further attacks by bioterrorists. This funding has enabled a multifaceted and comprehensive approach to civilian biodefense, involving the Department of Homeland Security and agencies of the Department of Health and Human Services, including the Center for Disease Control, the Food and Drug Administration and the National Institutes of Health (NIH).

The resources appropriated to the NIH alone for the conduct of biomedical research leading to the development of countermeasures against agents of bioterror were more than $1.5 billion in fiscal year 2003.

With this infusion of resources to the research enterprise come enormous responsibilities, which are taken very seriously. At NIH, we have rapidly accelerated research devoted to the prevention, diagnosis and treatment of diseases caused by potential agents of bioterrorism. While our efforts have focused on the "Category A" agents considered to be the most likely and potentially devastating bioterror threats (smallpox, anthrax, botulinum toxin, plague, tularemia and hemorrhagic fever viruses such as ebola), research is also being conducted on a much longer list of potential bioterror agents that pose significant threats to human health, as well as on chemical and radiological threats.

NIH has long sought to translate basic research findings into real-world interventions, but the path to product development has not been central to our research strategy. The terrible terrorist events in the fall of 2001 compelled us to change our approach. We remain committed to conducting the basic research that has served and will continue to serve as the underpinning of applied research and that approach has long been the strong suit of NIH, through its own scientists, grantees and contractors. However, given our vulnerability to terrorism in the post-September 11 world, we now have taken a proactive leadership role in facilitating the transition from basic to translational research and product development, and now think in terms of time frames that are uncharacteristically brief for biomedical research. In essence, we have developed an expanded paradigm, one in which we strike a balance between the time-honored goals of pursuing basic scientific research as the true foundation of all our objectives, and the need for leadership in the pursuit of applied research to develop rapidlybiodefense countermeasures.

In order to develop rapidly such countermeasures, we must engage our partners in industry in creative ways, and significantly bolster our interactions with the private sector, including both smaller biotechnology companies and large pharmaceutical corporations. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

The Power of Biomedical Research
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.